HK1024618A1 - Stable glassy state powder formulations. - Google Patents

Stable glassy state powder formulations.

Info

Publication number
HK1024618A1
HK1024618A1 HK00101575A HK00101575A HK1024618A1 HK 1024618 A1 HK1024618 A1 HK 1024618A1 HK 00101575 A HK00101575 A HK 00101575A HK 00101575 A HK00101575 A HK 00101575A HK 1024618 A1 HK1024618 A1 HK 1024618A1
Authority
HK
Hong Kong
Prior art keywords
powder formulations
glassy state
state powder
stable glassy
stable
Prior art date
Application number
HK00101575A
Other languages
English (en)
Inventor
Linda C Foster
Mei-Chang Kuo
Sheila R Billingsley
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24946736&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1024618(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of HK1024618A1 publication Critical patent/HK1024618A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0086—Inhalation chambers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/07—General characteristics of the apparatus having air pumping means
    • A61M2205/071—General characteristics of the apparatus having air pumping means hand operated
    • A61M2205/073—Syringe, piston type

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
HK00101575A 1996-10-17 2000-03-15 Stable glassy state powder formulations. HK1024618A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/733,225 US6258341B1 (en) 1995-04-14 1996-10-17 Stable glassy state powder formulations
PCT/US1997/018901 WO1998016205A2 (en) 1996-10-17 1997-10-14 Stable glassy state powder formulations

Publications (1)

Publication Number Publication Date
HK1024618A1 true HK1024618A1 (en) 2000-10-20

Family

ID=24946736

Family Applications (1)

Application Number Title Priority Date Filing Date
HK00101575A HK1024618A1 (en) 1996-10-17 2000-03-15 Stable glassy state powder formulations.

Country Status (21)

Country Link
US (1) US6258341B1 (xx)
EP (2) EP0941067B1 (xx)
CN (1) CN1124843C (xx)
AR (1) AR013854A1 (xx)
AT (1) ATE245969T1 (xx)
AU (1) AU734891B2 (xx)
CA (1) CA2274758C (xx)
CO (1) CO5011099A1 (xx)
DE (1) DE69723854T2 (xx)
DK (1) DK0941067T3 (xx)
EA (1) EA002055B1 (xx)
ES (1) ES2203792T3 (xx)
GE (1) GEP20032985B (xx)
HK (1) HK1024618A1 (xx)
HU (1) HUP0001108A3 (xx)
IL (1) IL130476A (xx)
NZ (1) NZ336171A (xx)
PT (1) PT941067E (xx)
TW (1) TW504389B (xx)
WO (1) WO1998016205A2 (xx)
ZA (1) ZA979145B (xx)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030113273A1 (en) * 1996-06-17 2003-06-19 Patton John S. Methods and compositions for pulmonary delivery of insulin
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6309671B1 (en) * 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
US20030203036A1 (en) 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
GB9703673D0 (en) * 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
CA2231968A1 (en) * 1998-03-11 1999-09-11 Smoke-Stop, A Partnership Consisting Of Art Slutsky Method of producing a nicotine medicament
US6956021B1 (en) * 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
US6234167B1 (en) 1998-10-14 2001-05-22 Chrysalis Technologies, Incorporated Aerosol generator and methods of making and using an aerosol generator
FR2787329B1 (fr) * 1998-12-17 2001-02-09 Aventis Pharma Sa Nouvelle application therapeutique des heparines de bas poids moleculaire
JP2002541213A (ja) 1999-04-13 2002-12-03 インヘール セラピューティック システムズ， インコーポレイテッド 不妊症の処置のための乾燥粉末処方物の肺投与
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US6586008B1 (en) 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
US6749835B1 (en) 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
CA2382821A1 (en) * 1999-08-25 2001-03-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
US20010036481A1 (en) * 1999-08-25 2001-11-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
US7252840B1 (en) 1999-08-25 2007-08-07 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles
ES2343124T3 (es) 1999-10-29 2010-07-23 Novartis Ag Composiciones de polvo seco con dispersabilidad mejorada.
JP4711520B2 (ja) * 2000-03-21 2011-06-29 日本ケミカルリサーチ株式会社 生理活性ペプチド含有粉末
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
EP1280520B2 (en) 2000-05-10 2018-03-21 Novartis AG Phospholipid-based powders for drug delivery
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
GB0011807D0 (en) * 2000-05-16 2000-07-05 Quadrant Holdings Cambridge Formulation for inhalation
US7575761B2 (en) 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
EP1305040B1 (en) * 2000-07-28 2009-09-09 Christopher J. Murphy Transplant media
FR2812545B1 (fr) * 2000-08-03 2003-03-28 Air Liquide Sante Int Aerosol medicamenteux inhalable dans le traitement ou la prevention de la douceur
WO2002015880A2 (en) * 2000-08-25 2002-02-28 Merck Patent Gmbh Powdered mannitol and mannitol-containing compositions
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
US6701921B2 (en) 2000-12-22 2004-03-09 Chrysalis Technologies Incorporated Aerosol generator having heater in multilayered composite and method of use thereof
US6799572B2 (en) 2000-12-22 2004-10-05 Chrysalis Technologies Incorporated Disposable aerosol generator system and methods for administering the aerosol
US6681998B2 (en) 2000-12-22 2004-01-27 Chrysalis Technologies Incorporated Aerosol generator having inductive heater and method of use thereof
US6491233B2 (en) 2000-12-22 2002-12-10 Chrysalis Technologies Incorporated Vapor driven aerosol generator and method of use thereof
US6501052B2 (en) 2000-12-22 2002-12-31 Chrysalis Technologies Incorporated Aerosol generator having multiple heating zones and methods of use thereof
US20020141946A1 (en) * 2000-12-29 2002-10-03 Advanced Inhalation Research, Inc. Particles for inhalation having rapid release properties
IL158192A0 (en) * 2001-05-04 2004-03-28 Pfizer Prod Inc Method of preventing type 2 diabetes with aerosolized insulin
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
WO2002094243A1 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of sumatriptan, frovatriptan or naratriptan through an inhalation route
US6568390B2 (en) 2001-09-21 2003-05-27 Chrysalis Technologies Incorporated Dual capillary fluid vaporizing device
US6640050B2 (en) 2001-09-21 2003-10-28 Chrysalis Technologies Incorporated Fluid vaporizing device having controlled temperature profile heater/capillary tube
US6702997B2 (en) 2001-10-26 2004-03-09 Dey, L.P. Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma
US20030140920A1 (en) * 2001-10-26 2003-07-31 Dey L.P. Albuterol inhalation soultion, system, kit and method for relieving symptoms of pediatric asthma
US20030191151A1 (en) * 2001-10-26 2003-10-09 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
US20030203930A1 (en) * 2001-10-26 2003-10-30 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
JP2003221335A (ja) 2001-10-26 2003-08-05 Dey Lp 慢性閉塞性肺疾患の症状を緩和するためのアルブテロールおよびイプラトロピウム吸入溶液、システム、キットおよび方法
US20030129250A1 (en) * 2001-11-20 2003-07-10 Advanced Inhalation Research Inc. Particulate compositions for improving solubility of poorly soluble agents
ES2415654T3 (es) * 2001-11-20 2013-07-26 Civitas Therapeutics, Inc. Composiciones particuladas mejoradas para suministro pulmonar
US6681769B2 (en) 2001-12-06 2004-01-27 Crysalis Technologies Incorporated Aerosol generator having a multiple path heater arrangement and method of use thereof
US6804458B2 (en) 2001-12-06 2004-10-12 Chrysalis Technologies Incorporated Aerosol generator having heater arranged to vaporize fluid in fluid passage between bonded layers of laminate
TWI324518B (en) 2001-12-19 2010-05-11 Nektar Therapeutics Pulmonary delivery of aminoglycosides
US6701922B2 (en) 2001-12-20 2004-03-09 Chrysalis Technologies Incorporated Mouthpiece entrainment airflow control for aerosol generators
US7258873B2 (en) * 2002-04-11 2007-08-21 Medimmune Vaccines, Inc. Preservation of bioactive materials by spray drying
AU2003234090A1 (en) 2002-04-11 2003-10-27 Medimmune Vaccines, Inc. Spray freeze dry of compositions for pulmonary administration
US20040042972A1 (en) * 2002-04-11 2004-03-04 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
WO2003090717A1 (en) * 2002-04-23 2003-11-06 Nanotherapeutics, Inc Process of forming and modifying particles and compositions produced thereby
GB0216562D0 (en) 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
AU2003228907A1 (en) * 2002-05-07 2003-11-11 Nektar Therapeutics Capsules for dry powder inhalers and methods of making and using same
KR20050088243A (ko) * 2002-12-30 2005-09-02 넥타르 테라퓨틱스 프리필름화 분무기
DE10306766A1 (de) * 2003-02-18 2004-08-26 Ino Therapeutics Gmbh Dosierte Abgabe eines therapeutischen Gases
CA2526475A1 (en) 2003-05-21 2004-12-02 Alexza Pharmaceuticals, Inc. Optically ignited or electrically ignited self-contained heating unit and drug-supply unit employing same
AU2004251623B2 (en) * 2003-05-28 2010-03-18 Novartis Ag Spray drying of an alcoholic aqueous solution for the manufacture of a water-in-soluble active agentmicroparticle with a partial or complete amino acid and/or phospholipid coat
AU2004263900A1 (en) 2003-08-08 2005-02-17 Arriva Pharmaceuticals, Inc. Methods of protein production in yeast
DE10339197A1 (de) * 2003-08-22 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknete amorphe Pulver mit geringer Restfeuchte und guter Lagerstabilität
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
JP2007509941A (ja) * 2003-10-28 2007-04-19 グラクソ　グループ　リミテッド ラクトース無水物を用いる吸入医薬製剤およびその投与方法
CA2545458A1 (en) * 2003-11-10 2005-05-26 Arriva-Prometic Inc. Dry recombinant human alpha 1-antitrypsin formulation
EP1701714A2 (en) 2004-01-07 2006-09-20 Nektar Therapeutics Improved sustained release compositions for pulmonary administration of insulin
RU2006141358A (ru) 2004-04-23 2008-05-27 Сайдекс, Инк. (Us) Препаративная форма для ингалятора сухого порошка, содержащая простой сульфоалкиловый эфир циклодекстрина
US20060039985A1 (en) * 2004-04-27 2006-02-23 Bennett David B Methotrexate compositions
US7611709B2 (en) 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
DE102004022928A1 (de) * 2004-05-10 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulver enthaltend neuartige Oligosacharidgemische und Verfahren zu deren Herstellung
DE102004022926A1 (de) * 2004-05-10 2005-12-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknete Pulver enthaltend zumindest ein 1,4 O-verknüpftes Saccharose-Derivat und Verfahren zu deren Herstellung
US7723306B2 (en) * 2004-05-10 2010-05-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
US7727962B2 (en) 2004-05-10 2010-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder comprising new compositions of oligosaccharides and methods for their preparation
CN105801686B (zh) 2004-07-19 2020-04-07 比奥孔有限公司 胰岛素-低聚物共轭物、制剂及其用途
CA2576344C (en) * 2004-08-11 2010-10-05 Cadbury Adams Usa Llc Warming compositions and delivery systems therefor
WO2006066595A2 (en) * 2004-12-22 2006-06-29 Novozymes A/S Recombinant production of serum albumin
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
EP1973523A2 (en) * 2005-12-15 2008-10-01 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
ES2594867T3 (es) 2007-03-09 2016-12-23 Alexza Pharmaceuticals, Inc. Unidad de calentamiento para usar en un dispositivo de administración de fármaco
GB0716026D0 (en) * 2007-08-16 2007-09-26 Norton Healthcare Ltd An inhalable medicament
US8268354B2 (en) 2007-11-07 2012-09-18 Aridis Pharmaceuticals Sonic low pressure spray drying
CA2760386A1 (en) * 2008-05-01 2009-11-05 Kanata Chemical Technologies Inc. Cationic transition-metal arene catalysts
US9827205B2 (en) * 2008-12-12 2017-11-28 Mallinckrodt Pharma Ip Trading D.A.C. Dry powder fibrin sealant
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
EP2410981B2 (en) 2009-03-26 2020-02-26 Pulmatrix Operating Company, Inc. Dry powder formulations and methods for treating pulmonary diseases
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
RU2580315C3 (ru) 2009-05-29 2021-06-18 Перл Терапьютикс, Инк. Композиции для респираторной доставки активных веществ и связанные с ними способы и системы
GB0918450D0 (en) 2009-10-21 2009-12-09 Innovata Ltd Composition
US8758824B2 (en) 2010-08-30 2014-06-24 Pulmatrix, Inc. Respirably dry powder comprising calcium lactate, sodium chloride and leucine
CN105640925B (zh) * 2010-08-30 2019-08-16 普马特里克斯营业公司 干燥粉末配方及用于治疗肺部疾病的方法
ES2899621T3 (es) 2010-09-29 2022-03-14 Pulmatrix Operating Co Inc Polvos secos catiónicos que comprenden sal de magnesio
KR101915241B1 (ko) 2010-09-29 2018-11-06 풀매트릭스 오퍼레이팅 컴퍼니, 인크 흡입용의 1가 금속 양이온 건조 분말
US9808030B2 (en) 2011-02-11 2017-11-07 Grain Processing Corporation Salt composition
EP2739268B1 (en) * 2011-08-01 2018-10-31 Monash University Method and formulation for inhalation
IN2014CN03555A (xx) 2011-10-25 2015-07-03 Onclave Therapeutics Ltd
US9744318B2 (en) 2011-12-16 2017-08-29 Novartis Ag Aerosolization apparatus for inhalation profile-independent drug delivery
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
CA2865972C (en) 2012-02-29 2022-01-04 Pulmatrix, Inc. Inhalable dry powders
SG11201507286QA (en) 2013-03-15 2015-10-29 Pearl Therapeutics Inc Methods and systems for conditioning of particulate crystalline materials
CA2907566C (en) 2013-04-01 2023-08-22 Pulmatrix, Inc. Tiotropium dry powders
EP2999460A1 (en) 2013-05-22 2016-03-30 Pearl Therapeutics, Inc. Compositions, methods&systems for respiratory delivery of three or more active agents
WO2014198004A1 (en) * 2013-06-11 2014-12-18 Biocartis Nv Biomolecule drying process for long-term storage
BR112016000937A8 (pt) * 2013-07-18 2021-06-22 Mannkind Corp formulações farmacêuticas de pó seco, método para a fabricação de uma formulação de pó seco e uso de uma formulação farmacêutica de pó seco
CN105722392B (zh) * 2013-11-22 2019-07-23 默沙东公司 非核苷逆转录酶抑制剂的组合物
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
AU2015331915A1 (en) * 2014-10-16 2017-05-25 Teva Branded Pharmaceutical Products R&D, Inc. Dry powder formulation
CN107106641B (zh) * 2014-10-31 2021-12-21 葛兰素史密斯克莱知识产权发展有限公司 粉末制剂
AR102869A1 (es) 2014-12-16 2017-03-29 Lilly Co Eli Composiciones de insulina de rápida acción
WO2016176552A1 (en) * 2015-04-30 2016-11-03 Otitopic Inc. Dry power formulations for inhalation
CN108498917A (zh) * 2015-05-16 2018-09-07 苏州汉方医药有限公司 由手动悬浮微颗粒发生器和复方何首乌组成的药盒
JP2019534328A (ja) 2016-10-31 2019-11-28 ベクチュラ リミテッド 組成物、方法及び使用
US20190343768A1 (en) * 2018-05-14 2019-11-14 Dance Biopharm Inc. Insulin formulations for reconstitution into high concentration liquid solutions
GB201817861D0 (en) * 2018-11-01 2018-12-19 Nicoventures Trading Ltd Gel and crystalline powder
CN113476428B (zh) * 2021-01-28 2022-03-29 朗天药业(湖北)有限公司 一种吸入用硫酸沙丁胺醇溶液及其制备方法
CN112956693A (zh) * 2021-02-26 2021-06-15 深圳大学 一种应急食品及其制备方法
MX2024000468A (es) 2021-07-09 2024-04-05 Astrazeneca Pharmaceuticals Lp Composiciones, metodos y sistemas para la administracion de farmacos en aerosol.
CN118414148A (zh) 2021-12-20 2024-07-30 阿斯利康(瑞典)有限公司 用于气溶胶药物递送的组合物、方法和系统
WO2023212191A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Combination of albuterol and budesonide for the treatment of asthma

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818542A (en) 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
US4891319A (en) 1985-07-09 1990-01-02 Quadrant Bioresources Limited Protection of proteins and the like
GB8903593D0 (en) * 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
US5098955A (en) 1989-09-18 1992-03-24 Ppg Industries, Inc. Powder coating composition low Tg and high Tg polymers with acid groups
US5057392A (en) 1990-08-06 1991-10-15 Eastman Kodak Company Low fusing temperature toner powder of cross-linked crystalline and amorphous polyester blends
US5200399A (en) 1990-09-14 1993-04-06 Boyce Thompson Institute For Plant Research, Inc. Method of protecting biological materials from destructive reactions in the dry state
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
AU659645B2 (en) 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
JP2546089B2 (ja) * 1991-07-09 1996-10-23 上村工業株式会社 錫又は半田めっき浴への金属イオン補給方法
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
KR100419037B1 (ko) * 1994-03-07 2004-06-12 넥타르 테라퓨틱스 폐를통한인슐린의전달방법및그조성물
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
CA2190502A1 (en) * 1994-05-18 1995-11-23 Robert M. Platz Methods and compositions for the dry powder formulation of interferons
EP0773781B1 (en) * 1994-08-04 2003-10-22 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
CA2218074C (en) * 1995-04-14 2002-10-08 Mohammed Eljamal Powdered pharmaceutical formulations having improved dispersibility
GB9508691D0 (en) 1995-04-28 1995-06-14 Pafra Ltd Stable compositions
US5826633A (en) 1996-04-26 1998-10-27 Inhale Therapeutic Systems Powder filling systems, apparatus and methods

Also Published As

Publication number Publication date
EP0941067B1 (en) 2003-07-30
HUP0001108A2 (hu) 2000-08-28
CA2274758A1 (en) 1998-04-23
AU5083498A (en) 1998-05-11
TW504389B (en) 2002-10-01
WO1998016205A3 (en) 1998-09-03
DK0941067T3 (da) 2003-11-17
US6258341B1 (en) 2001-07-10
CN1240349A (zh) 2000-01-05
DE69723854T2 (de) 2004-04-22
EA002055B1 (ru) 2001-12-24
ATE245969T1 (de) 2003-08-15
EP1342469A2 (en) 2003-09-10
IL130476A (en) 2005-05-17
ZA979145B (en) 1998-05-11
NZ336171A (en) 2001-06-29
GEP20032985B (en) 2003-06-25
AR013854A1 (es) 2001-01-31
EP0941067A2 (en) 1999-09-15
EP1342469A3 (en) 2004-01-21
IL130476A0 (en) 2000-06-01
EA199900454A1 (ru) 1999-12-29
ES2203792T3 (es) 2004-04-16
HUP0001108A3 (en) 2000-11-28
PT941067E (pt) 2003-12-31
WO1998016205A2 (en) 1998-04-23
DE69723854D1 (de) 2003-09-04
CA2274758C (en) 2009-09-29
CO5011099A1 (es) 2001-02-28
CN1124843C (zh) 2003-10-22
AU734891B2 (en) 2001-06-28

Similar Documents

Publication Publication Date Title
ZA979145B (en) Stable glassy state powder formulations.
GB9715751D0 (en) Formulations
ZA984697B (en) Stable insulin formulations.
IL116459A0 (en) Powder formulations
EP1049486A4 (en) GLP-1 FORMULATIONS
PL343021A1 (en) Formulations
AU7389098A (en) Local anesthetic formulations
ZA976777B (en) Anthelmintic formulations.
AU3261297A (en) New insecticide formulations
SI0884053T1 (en) Stable insulin formulations
IL127655A0 (en) Pesticidal tablet formulations
IL128589A0 (en) Explosive formulations
ZA993473B (en) Pellet formulations.
GB9806312D0 (en) Novel formulations
GB9815002D0 (en) Formulations
GB9815001D0 (en) Formulations
IL126664A0 (en) Explosive formulations
IL126663A0 (en) Explosive formulations
GB9605948D0 (en) Novel formulations
GB9810181D0 (en) Novel formulations
HUP9903910A3 (en) Insect-repellent formulations
SI0941067T1 (en) Stable glassy state powder formulations
IL126669A0 (en) Explosive formulations
GB9703099D0 (en) Formulations
GB9703100D0 (en) Formulations

Legal Events

Date Code Title Description
PF Patent in force
REV Revocation after opposition
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20101014